Please login to the form below

Not currently logged in


This page shows the latest Galapagos news and features for those working in and with pharma, biotech and healthcare.

Edging Evolution

Edging Evolution

Darwin was interested in how this process led to change in phenotypic traits like the beaks of Galapagos finches.

Latest news

More from news
Approximately 9 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    This adds to the good news for Vertex, which saw AbbVie and Galapagos also post disappointing results for their triple therapy candidate.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

  • Deal Watch May 2016 Deal Watch May 2016

    271. Galapagos/ AbbVie. Agreement extension. Cystic fibrosis alliance for development of a triple combination therapy; increase in milestones from $350m to $600m.

  • Deal Watch December 2015 Deal Watch December 2015

    therapy areas such as oncology and, this month inflammatory disease, following the licensing deal with Galapagos for over $2bn. ... Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    195+. Galapagos/ Charles River. Acquisition of CRO business. Drug discovery services business.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...